touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache.
The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What is the rationale for using intranasal ketamine in the acute treatment of refractory headache? (0:21)
- Could you tell us a little about your retrospective study and its patient population? (1:10)
- What were the study efficacy and safety findings? (2:57)
- What is the ideal dosing of intranasal ketamine in adults? (4:40)
- Who is likely to benefit most from intranasal ketamine and in whom is it contraindicated? (6:02)
Disclosures: Within the past 24 months, Michael Marmura has received compensation for consultation from Alder/Lumbeck, Lilly, Supernus, and Theranica; has participated in speaker bureaus for Eli Lilly, and Amgen/Novartis; has received institutional support for serving as principal investigator from Teva, GammaCore and Allergan/AbbVie; and has received payments for authorship or royalties from Demos Medical, Cambridge University Press and MedLink.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!